InMed Pharmaceuticals: ADAR1 funds buy 2,640 shares

The purchase followed a 1-for-10 reverse split; the issuer completed a merger and changed its name and trading symbol the next day.

Available on EDGAR 11/09/2026 - 08:18 PM EST Accepted by SEC EDGAR 11/09/2026 - 08:18 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. (INM) reported that private investment funds managed by ADAR1 Capital Management, LLC purchased 2,640 common shares on November 5, 2026, at a weighted average price of $13.0953 per share; the purchases ranged from $12.9500 to $13.3000. The reported position following the purchase was 98,297 shares. The funds’ shares may be deemed indirectly beneficially owned by ADAR1 and Daniel Schneeberger, ADAR1’s sole manager; each reporting person disclaimed beneficial ownership except to the extent of any pecuniary interest. The purchase followed the issuer’s 1-for-10 reverse stock split on November 4. On November 6, the issuer completed its previously announced merger, changed its name to Mentari Therapeutics, Inc. and its trading symbol to MTRI, and the reporting persons ceased to beneficially own more than 10% of the issuer’s outstanding common stock and were no longer subject to Section 16.

Insider Trade Summary

Net Buyer: 2,640 shares

Net Buy 1 txn

Insider ADAR1 Capital Management, LLC, Schneeberger Daniel

Role 10% Owner | 10% Owner

Bought 2,640 shs ($35K)

Increase in Position 2.8%

Type	Security	Shares	Price	Value
Purchase	Common Shares F1, F2, F3, F4	2,640	$13.0953	$35K

Holdings After Transaction: Common Shares — 98,297 shares (Indirect, See Footnote)

Holdings Before and After: Common Shares, 95,657 to 98,297 shares (Indirect, See Footnote)

Footnotes (4)

1. F1. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.9500 to $13.3000, inclusive. Each Reporting Person undertakes to provide to Mentari Therapeutics, Inc., any security holder of Mentari Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. F2. On November 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its outstanding common stock. The transaction reported herein occurred on November 5, 2026, after giving effect to the reverse stock split. On November 6, 2026, the Issuer completed its previously announced merger transaction and changed its name from InMed Pharmaceuticals Inc. to Mentari Therapeutics, Inc. and its trading symbol from INM to MTRI. Following completion of the merger and related transactions, the Reporting Persons ceased to beneficially own more than 10% of the Issuer's outstanding common stock and are no longer subject to Section 16.
3. F3. The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
4. F4. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Key Figures

Common shares purchased: 2,640 shares Weighted average purchase price: $13.0953 per share Purchase price range: $12.9500 to $13.3000 per share +2 more

5 metrics

Common shares purchased 2,640 shares November 5, 2026

Weighted average purchase price $13.0953 per share November 5, 2026

Purchase price range $12.9500 to $13.3000 per share Prices for the multiple purchases

Reported shares following purchase 98,297 shares Following the November 5, 2026 purchase

Reverse stock split 1-for-10 Effective November 4, 2026

Key Terms

weighted average price, reverse stock split, beneficial ownership, pecuniary interest

4 terms

weighted average price financial

"The reported price is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

reverse stock split financial

"effected a 1-for-10 reverse stock split"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

beneficial ownership regulatory

"disclaims beneficial ownership"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest regulatory

"except to the extent of his/its pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many INM shares were purchased, and at what price?

Private investment funds managed by ADAR1 Capital Management, LLC purchased 2,640 common shares on November 5, 2026, at a weighted average price of $13.0953 per share. The purchases were made at prices ranging from $12.9500 to $13.3000.

Who was associated with the INM share purchase?

The shares were owned directly by private investment funds managed by ADAR1 Capital Management, LLC. The shares may be deemed indirectly beneficially owned by ADAR1 and Daniel Schneeberger, ADAR1’s sole manager; each reporting person disclaimed beneficial ownership except to the extent of any pecuniary interest.

Was the INM purchase made after a reverse stock split?

Yes. The issuer effected a 1-for-10 reverse stock split on November 4, 2026, and the November 5 purchase occurred after giving effect to the split.

What happened to the reporting persons’ status after the INM purchase?

Following completion of the merger and related transactions on November 6, 2026, the reporting persons ceased to beneficially own more than 10% of the issuer’s outstanding common stock and were no longer subject to Section 16.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ADAR1 Capital Management, LLC

(Last) (First) (Middle)

3503 WILD CHERRY DRIVE

BUILDING 9

(Street)

AUSTIN TEXAS 78738

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ MTRI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	11/05/2026		P		2,640	A	$13.0953(1)	98,297(2)	I	See Footnote(3)(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

ADAR1 Capital Management, LLC

(Last) (First) (Middle)

3503 WILD CHERRY DRIVE

BUILDING 9

(Street)

AUSTIN TEXAS 78738

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Schneeberger Daniel

(Last) (First) (Middle)

3503 WILD CHERRY DRIVE

BUILDING 9

(Street)

AUSTIN TEXAS 78738

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.9500 to $13.3000, inclusive. Each Reporting Person undertakes to provide to Mentari Therapeutics, Inc., any security holder of Mentari Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. On November 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its outstanding common stock. The transaction reported herein occurred on November 5, 2026, after giving effect to the reverse stock split. On November 6, 2026, the Issuer completed its previously announced merger transaction and changed its name from InMed Pharmaceuticals Inc. to Mentari Therapeutics, Inc. and its trading symbol from INM to MTRI. Following completion of the merger and related transactions, the Reporting Persons ceased to beneficially own more than 10% of the Issuer's outstanding common stock and are no longer subject to Section 16.

3. The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

4. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

	ADAR1 Capital Management, LLC By: Daniel Schneeberger, Manager /s/ Daniel Schneeberger	11/09/2026
	/s/ Daniel Schneeberger	11/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)